6108 — New Ray Medicine International Holding Income Statement
0.000.00%
Last trade - 00:00- HK$76.90m
- HK$16.20m
- HK$93.95m
Annual income statement for New Ray Medicine International Holding, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 133 | 335 | 89.8 | 50.2 | 93.9 |
| Cost of Revenue | |||||
| Gross Profit | 10.9 | 28.5 | -34.8 | 11.3 | -1.62 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 177 | 335 | 165 | 68.4 | 120 |
| Operating Profit | -43.4 | 0.215 | -75.5 | -18.2 | -26.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -69.9 | -3.61 | -80.3 | -22.3 | -32.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -69.7 | -2.82 | -77.9 | -22.2 | -31 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -69.7 | -2.82 | -77.9 | -22.2 | -31 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -69.7 | -2.82 | -77.9 | -22.2 | -31 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.025 | -0.001 | -0.047 | -0.012 | -0.019 |